Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome

What is Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome?

Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is a rare congenital disorder that affects the female reproductive system. This condition is characterized by an underdeveloped vagina and uterus. The uterus may be small or absent and the vagina is typically shortened. People with MRKH have normally-functioning ovaries and a female chromosome pattern. MRKH occurs when a fetus is developing and is present in about 1 in every 4,500 females at birth.

External genitalia and secondary sexual characteristics, like pubic hair and breasts, develop normally. However, people with MRKH typically do not experience menstrual cycles.

Due to an underdeveloped or absent uterus, people with the condition cannot carry a pregnancy and therefore have Uterine Factor Infertility (UFI). Individuals who had the uterus surgically removed or have a uterus that does not function properly also have UFI. UFI is a previously irreversible form of female infertility that affects as many as 5 percent of reproductive-aged women worldwide.

Types of MRKH syndrome

Mayer-Rokitansky-Küster-Hauser syndrome cases are generally broken into two types:

  • In MRKH syndrome type 1, the uterus and upper vagina are abnormal, but other organs are unaffected.
  • In MRKH syndrome type 2, women experience abnormalities in other organs as well (most often the fallopian tubes, and commonly the kidneys and the spine).

In the majority of MRKH cases, an underdeveloped uterus makes it impossible to carry a baby. Nevertheless, healthy ovaries make it possible to have a biological child via assisted reproduction.

Symptoms of MRKH

A nonexistent menstrual period by age 16 is often one of the first signs of MRKH syndrome, but there may be other symptoms.

Symptoms of MRKH type 1 include:

  • Painful or difficult sexual intercourse
  • Reduced vaginal depth and width

Symptoms of MRKH type 2 are similar to type 1, but may also include:

  • Kidney complication or failure due to abnormal kidney formation or positioning, or a missing kidney
  • Skeletal abnormalities (most commonly of the spinal vertebrae)
  • Minor hearing loss
  • Heart defects
  • Other organ-related complications

Diagnosis of Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome

Diagnosis for type 1 Mayer-Rokitansky-Küster-Hauser syndrome often happens in later adolescence, when a young woman hasn’t started her period. A type 2 diagnosis can be prompted by an absent period or a wide range of other organ-related symptoms or abnormalities, sometimes at an earlier age.

Because shortened vaginal depth is often linked to MRKH, at the first sign of MRKH, doctors might use a device or gloved finger to gauge the vagina’s depth before ordering a pelvic ultrasound or MRI. The ultrasound will show whether a uterus or womb is present, and it can confirm the presence of fallopian tubes and kidneys.

Uterus Transplant

Penn Medicine’s ongoing Uterus Transplantation for Uterine Factor Infertility (UNTIL) trial, which launched in 2017, is a potential treatment option for people with MRKH and other forms of UFI. The UNTIL trial is currently the only U.S. uterus transplant trial that is actively enrolling patients.

In November 2019, a woman enrolled in the UNTIL trial delivered the second baby in the nation to be born following transplantation of a uterus from a deceased donor.

Many other programs around the globe have focused on transplantation exclusively from living donors, and to date, there have been approximately 70 uterus transplants globally. However, Penn Medicine’s trial is one of few to explore donation from both living or deceased donors — an approach that has the potential to expand the pool of organs available for transplantation and allows investigators the opportunity to directly compare outcomes from the different types of donors.

Patient stories

Finding triple-negative breast cancer at 33, she chose ‘Team Penn’

Shocked to learn she had stage III breast cancer, Kate Korson knew just where to go. She flew home to Penn Medicine, where a clinical trial saved her life.

A grateful patient pays it forward to treat uterine cancers

Dalia Jakas credits her doctor with curing her uterine cancer without harming her quality of life. Now, she’s paying it forward for future patients.

New lungs, a new liver, and a new lease on life

Decades after a childhood diagnosis of cystic fibrosis, Donald traveled across the world to find transplant care he could trust at Penn Medicine.

Home-assisted ventilation for autoimmune disease: Kim’s story

A rare autoimmune disease kept Kim Day from his favorite outdoor hobbies, until he met doctors in the Fishman Program for Home Assisted Ventilation.

ECMO saves recovering cancer survivor from lung failure

From cancer survivor to lung failure, Joey Porch’s journey took a miraculous turn with the help of the Penn Lung Rescue team

The road to recovery begins at home

Penn Medicine’s SNF at Home pilot program offers a seamless transition from the hospital to home with extra support to recover in familiar surroundings.

How home care connects real-life settings to patients’ healing

At-home care means helping people within their real environment, a personalized approach to care in the local community.

In the face of skin cancer, proton made all the difference

A Lancaster man and father of two reveals how proton therapy helped him beat skin cancer and reclaim his life.

70-year-old bench press competitor tackles rare cancer

While receiving treatment at Penn for a rare cancer, bench press competitor Howard Aaron continued to make fitness an essential part of his life.

Epilepsy surgery gives patient a new lease on life

Minimally invasive laser interstitial thermal therapy (LITT) surgery reduced the epilepsy symptoms a patient had experienced for more than 30 years.

Schedule an appointment

We can help you schedule an appointment or you can search our directory of specialists.